Speakers' Book

Developing Countries Vaccine Manufacturers Network
18th Annual General Meeting

25 - 28th September 2017, Seoul, S. Korea.

Developing Countries Vaccine Manufacturers Network

Annual General Meeting 2017
Speakers' Book

dcvmn
Developing Countries Vaccine Manufacturers Network

Annual General Meeting 2017
Speakers' Book

Day 1, 25th Sept 2017	9:00 - 12:30	PATH /UNICEF/WHO workshop on Innovative Solutions for Vaccine Supply and Distribution
Chair: **Ms. Debra Kristensen** 	Director, Vaccine and Pharmaceutical Technologies, PATH	Debra Kristensen oversees PATH's work in vaccine and pharmaceutical formulation, delivery and packaging, and supply systems and equipment. She is responsible for portfolios of projects centered on advancing product and system innovations that reduce costs, ease logistics, improve safety, expand coverage, and maximize public health impact in low-resource settings.
Co-chair: **Ms. Helen Kim** 	Team Leader, Vaccine Development & Regulatory Affairs, LG Chem, Ltd	Ms. Hyung-Shin (Helen) Kim is a specialist in Development and Regulatory Affairs of vaccines. She is Team Leader of Vaccine Development and Regulatory Affairs in Life Science R&D of LG Chem and has 18 years of professional experience in development, clinical trials and regulatory affairs of biopharmaceutical products, especially vaccines.
Mr. Darin Zehrung 	Portfolio Leader, Vaccine and Pharmaceutical Delivery Technologies, PATH	Darin Zehrung is a global health professional with more than 20 years of technical, business, and research experience with innovations and interventions to address public health challenges in low-resource settings. He is the Portfolio Leader of PATH's Vaccine and Pharmaceutical Delivery Technologies team, overseeing work in delivery and packaging technologies for vaccines and essential medicines.
Ms. Ulrike Kreysa 	Vice President Healthcare, GS1	Ulrike Kreysa is responsible for the Healthcare sector at GS1 and leads the development an implementation of GS1 standards in the healthcare industry to improve patient safety. She manages the global GS1 user group, formed by the stakeholders in the healthcare supply chain and works regularly with regulatory bodies to drive global harmonization.

Ms. Anna-Lea Kahn 	Technical Officer, EPI/IVB, WHO	Ms. Anna-Lea Kahn works in the Expanded Program on Immunization at the World Health Organization, focusing on logistics and innovation since 2014. Previously, she spent ten years in the research and policy team of the Polio Eradication Initiative. She earned her MSc from the London School of Hygiene and Tropical Medicine.
Dr. Andrew Meek 	Scientist, HIS/EMP/RHT/PQT, WHO	1987 : PhD in Molecular Virology (ANU) 1989-2005: Therapeutic Goods Administration [regulation of vaccines and other biologics] included WHO collaborative centre activities. 2005-2006 (WHO Iran): project manager - strengthening NRA's vaccine regulation. 2007- to date: WHO, Prequalification Team (PQT) with focus on quality and programmatic suitability aspects of vaccines.
Mr. Ian Lewis 	Contract Specialist, Vaccine Centre, UNICEF Supply Division	Mr. Lewis is working at UNICEF Supply Division in the Polio Unit within the Vaccine Centre. Main responsibilities are the supply management of IPV and OPV vaccines.

Annual General Meeting 2017
Speakers' Book

Day 1, 25th Sept 2017	17:30 – 18:30	Satellite Symposium on Innovative Technologies
Chair: **Mr. Michael Payne** 	Principal Consultant, Merck Millipore	Mr. Payne is Principal Technical Consultant at Merck Millipore. He previously worked as BPS Validation Support Manager, Asia, and managed Millipore's global technical training department for 10 years. He is responsible for filtration and separations regulatory and troubleshooting support in Asia. He holds a bachelor's degree in Chemical Engineering (Bioprocessing) from the UNSW, Sydney.
Co-Chair: **Dr. Guenter Jagschies** 	Senior Director Strategic Customer Relations, GE Healthcare Life Sciences	Günter Jagschies is Senior Director Strategic Customer Relations with GE Healthcare Life Sciences. Günter is working globally with industrial R&D collaborations and as an advisor for the GE Healthcare BioProcess R&D and Business team. He is the editor of a textbook "Biopharmaceutical Processing" and holds a PhD in Biochemistry from the University of Münster, Germany.
Dr. Sudeep Kothari 	Former IVI Senior Scientist	Dr. Kothari is former Senior Research Scientist at IVI leading the transfer of vaccine production processes developed at IVI to vaccine manufacturers in developing countries. Before joining IVI he had worked for Biological E and Panacea Biotech. He holds a BSc degree in Sciences, a MSc. in Applied Microbiology and a PhD. in Chemical Engineering.
Mr. Michael Rush 	Executive Director, Temptime Corporation	Michael Rush is the Executive Director of Global Health Policy for Temptime Corporation, responsible for developing policies for improving patient health. Prior to joining Temptime, Mike worked 13 years for Merck Vaccines; in vaccine public sector access, funding and policies. He holds a BA in Industrial Psychology and an MBA in International Business Administration.

Dr. Longding Liu 	Scientist, Institute of Medical Biology	Dr. Liu has more than 26 years of experience in vaccinology and virology. After graduating from Peking Union Medical College as PhD in Immunology, he focused on enterovirus research and vaccine development in Institute of Medical Biology. In recent 10 years, Longding devoted himself to EV71 inactivated vaccine (Human diploid cell) research and clinical study.
Dr. Mats Lundgren 	Director, GE Healthcare Life Sciences	Dr. Mats Lundgren has more than 25 years of experience in vaccinology; as Customer Applications Director at GE, Mats helps companies to implement modern processes with the goal of achieving more efficient production and higher vaccine quality. He holds PhD in Immunology, Cell, and Molecular Biology and a post-doctoral training.

DAY 2, 26th September 2017		
Day 2, 26th Sept 2017	**9:00 – 10:15**	**Opening Session**
Chair: **Ms. Mahima Datla** 	Managing Director, Biological E	Mahima Datla oversees strategic operations within Biological E organization and related to public policy. She has been with BE for 19 years and has served across a diverse range of functions. Mahima is also the President of DCVMN's Executive Committee, and is currently a member of CII National Biotech committees and a GHIT fund board member.
Co-Chair: **Dr. Mahnhoon Park** 	CEO, SK Chemicals	Dr. Mahnhoon Park is the CEO of SK Chemicals leading the entire biopharmaceutical business of the company. Particularly, based on his virology expertise and 35 years of experiences within the industry, he built up the existing vaccine business as the most important strategic initiative of the company that covers technologies, manufacturing infrastructure and product portfolio.
Mr. Jae Yong Ahn 	Executive Vice President, Vaccines Business, SK Chemicals	Mr. Jae Yong Ahn is Executive Vice President, the Head of Vax Business Group at SK Chemicals, responsible for the entire vaccine business from R&D, manufacturing up to marketing. He has a variety of experiences in strategic planning, HR and corporate culture, while he holds MBA from the University of Chicago, USA as educational background.
Dr. Seth Berkley 	CEO, Gavi, The Vaccine Alliance	M.D. and epidemiologist, Dr. Seth Berkley joined Gavi, as its CEO in 2011. Under his leadership Gavi has now reached more than half a billion children in the 73 poorest countries. In 2015 he led Gavi to raise US$ 7.5 billion to support the immunization of 300 million children by 2020.

Day 2, 26th Sept 2017	10:45 – 12:30	Epidemic/Pandemic Forum
Chair: **Dr. Alexander Precioso** 	Clinical Director, Instituto Butantan	Alexander R Precioso is Clinical Director of Instituto Butantan, São Paulo with expertise in Clinical Trials, Epidemiology, Pediatrics and vaccine research. He has been responsible for coordinating the integration between the Project Management Office, the Technology Transfer Office, and The Innovation Technology Unit at Butantan institute since 2015.
Co-Chair: **Mr. Mahendra Suhardono** 	Past DCVMN President, Indonesia	Mahendra has nearly 30 years of experience in biologicals products business. For the past 10 years, he holds positions of increasing responsibilities as a top management in BioFarma, a vaccine company in Indonesia. He is the past-President of DCVMN, where he served for two terms, from 2012 to 2016.
Dr. Richard Hatchett 	CEO, CEPI (Coalition for Epidemic Preparedness Innovations)	Dr. Hatchett has led medical countermeasure development programs at BARDA and the U.S. NIH. He has played leading roles at HHS and the White House in designing these programs as well as in planning for and responding to H5N1 avian influenza, the 2009 H1N1 influenza pandemic, Ebola, MERS, and Zika epidemics.
Dr. Sylvie Briand 	Director, WHO Health Emergencies Programme	Dr. Briand is Director of the Infectious Hazard Management department (IHM) in the new Health Emergencies programme at WHO headquarters in Geneva, Switzerland. IHM develops global strategies to prevent and control epidemic-prone diseases under the International Health Regulations. Prior to joining WHO, she worked for a private consulting agency developing international public health projects.

Dr. Jerome Kim 	Director General, IVI (International Vaccine Institute)	Director General International Vaccine Institute Jerome Kim, M.D. Director-General of the International Vaccine Institute (IVI, is an international expert on the evaluation and development of vaccines. He has strong scientific experience spans basic research through advanced clinical development.
Day 2, 26th Sept 2017	**11:45 – 12:30**	**Epidemic/Pandemic Panel Discussion**
Moderator: **Dr. Martin Friede** 	Coordinator, IVR, WHO	Martin Friede is the coordinator of the Initiative for Vaccine research (IVR) at the World Health Organization in Geneva, Switzerland. In this position Dr. Friede provides leadership to WHO's activities on vaccine research including development of vaccine research policies, strategies and priorities. He also leads the WHO Blueprint for R&D to prevent epidemics.
Dr. Odile Leroy 	Executive Director, EVI (European Vaccine Initiative)	At EVI, Dr. Leroy is managing 16 vaccine projects on diseases of poverty and leading 7 EC/EDCTP/IMI funded projects, including the infrastructure project TRANSVAC. She has 30 years of vaccine R&D experience, as scientist in Africa, Corporate Clinical Director at Sanofi Pasteur, and leading 3 European Organizations (EMVI, EDCTP, and EVI)
Dr. Alexander Precioso 	Clinical Director, Instituto Butantan	Alexander R Precioso is Clinical Director of Instituto Butantan, São Paulo with expertise in Clinical Trials, Epidemiology, Pediatrics and vaccine research. He has been responsible for coordinating the integration between the Project Management Office, the Technology Transfer Office, and The Innovation Technology Unit at Butantan institute since 2015.

Dr. Maurício Zuma Medeiros 	General Director, BioManguinhos	Dr. Zuma is General Director of Bio-Manguinhos, the Institute of Technology on Immunobiologicals of Fiocruz. He has been a manager for 30 years in various areas of management, focused on results and a permanent search for management solutions for the advancement of public management. He is D.Phil. in Technology and Innovation Management by SPRU/University of Sussex – UK.
Mr. Samir Desai 	Sr. Vice President & SBU Head Zydus Cadila Healthcare Ltd.	Industry experience of close to 3 decades having handled sales, training, brand management, marketing and commercial operations. Current role includes commercial operations for vaccines & biologics and small molecules across specialties & geographies, Business Development, In & Out licensing, portfolio planning. Extensively worked in the area of maternal health related public policy advocacy.
Dr. Richard Hatchett 	CEO, CEPI (Coalition for Epidemic Preparedness Innovations)	Dr. Hatchett has led medical countermeasure development programs at BARDA and the U.S. NIH. He has played leading roles at HHS and the White House in designing these programs as well as in planning for and responding to H5N1 avian influenza, the 2009 H1N1 influenza pandemic, Ebola, MERS, and Zika epidemics.

Day 2, 26th Sept 2017	14:00 – 15:30	Innovative Partnerships Forum
Chair: Dr. Krishna Ella 	Chairman and Managing Director of Bharat Biotech International	Dr. Krishna Ella, graduated from the UW - Madison and founded Bharat Biotech in 1996. Bharat has been awarded as best innovative company by the Prime minister, ET Now, and CII. Bharat is the first company in the world to file global patens on Chikungunya and Zika vaccines.
Co-Chair: Dr. M. Friede 	Coordinator, IVR, WHO	Martin Friede is the coordinator of the Initiative for Vaccine research (IVR) at the World Health Organization in Geneva, Switzerland. In this position Dr. Friede provides leadership to WHO's activities on vaccine research including development of vaccine research policies, strategies and priorities. He also leads the WHO Blueprint for R&D to prevent epidemics.
Dr. Bernadette ABELA-RIDDER 	Team Leader, WHO	Dr Bernadette Abela-Ridder is Team Leader, Neglected Zoonotic Diseases unit in the Department for the Control of Neglected Tropical Diseases (NTDs) of WHO. In this capacity, she is responsible for human-animal aspects and zoonotic NTDs. She is the WHO focal Point on rabies.
Dr. Odile Leroy 	Executive Director, EVI (European Vaccine Initiative)	At EVI, Dr. Leroy is managing 16 vaccine projects on diseases of poverty and leading 7 EC/EDCTP/IMI funded projects, including the infrastructure project TRANSVAC. She has 30 years of vaccine R&D experience, as scientist in Africa, Corporate Clinical Director at Sanofi Pasteur, and leading 3 European Organizations (EMVI, EDCTP, and EVI)

Prof. William K. Ampofo 	Head, Noguchi Memorial Institute for Medical Research, University of Ghana	Professor William Kwabena Ampofo is Head, Virology Department, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana. His work spans molecular and serological investigations, anti-viral therapy and viral disease burden. William is Chair, African Vaccine Manufacturing Initiative and Ghana Ambassador African Society for Laboratory Medicine.
Dr. Andrin Oswald 	Director, Life Sciences Partnerships, BMGF	Dr. Oswald, is the director of Life Sciences Partnerships at the foundation, overseeing the foundation's engagements with corporations. Before joining the foundation in 2016, he was the CEO and Division Head of Novartis Vaccines and Diagnostics from 2008 to 2015. He obtained his medical degree from University of Geneva.
Day 2, 26th Sept 2017	**16:00-17:00**	**Innovative Partnerships Panel Discussion**
Moderator: **Dr. Glenn Rockman** 	Partner, GHIF	Mr. Rockman started his career at J.P. Morgan, where he spent more than 10 years working with non-profit organizations, including 3 years with the firm's impact investing unit. He led J.P. Morgan's work with the Gates Foundation to launch the Global Health Investment Fund, where he is currently a Partner.
Dr. Morena Makhoana 	CEO, BIOVAC	Morena is the CEO of Biovac, aiming to build vaccine manufacturing capacity in Southern Africa. Morena is a medical graduate from the University of Cape Town, South Africa. Prior to his CEO role he was Deputy CEO and Medical Affairs Director for Biovac and Litha Healthcare Group. He serves several of committees within the vaccine industry.

Dr. Krishna Ella 	Chairman & Managing Director, Bharat Biotech International	Dr. Krishna Ella, graduated from the UW - Madison and founded Bharat Biotech in 1996. Bharat has been awarded as best innovative company by the Prime minister, ET Now, and CII. Bharat is the first company in the world to file global patens on Chikungunya and Zika vaccines.
Dr. Bernadette ABELA-RIDDER 	Team Leader, WHO, NTD	Dr. Bernadette Abela-Ridder is Team Leader, Neglected Zoonotic Diseases unit in the Department for the Control of Neglected Tropical Diseases (NTDs) of WHO. In this capacity, she is responsible for human-animal aspects and zoonotic NTDs. She is the WHO focal Point on rabies.
Dr. Peter Khoury 	CEO, Nanotherapeutics	Dr. Khoury is President & CEO of Nanotherapeutics. Before that, he was with the BMGF, as Senior Program Officer, Life Sciences Partnerships, Office of the President for Global Health. He spearheaded the expansion of engagements with the developing countries manufacturers' industry. Previously, he was Vice-President, Global Marketing at Baxter International, and spent 10 years at Merck&Co., in positions of growing responsibilities. He holds a Ph.D. in microbiology and a MBA degree.
Mr. Alejandro Gil 	President, Sinergium Biotech	Alejandro Gil serves as President at Sinergium Biotech, a company that provides world class vaccines and biotechnological products. Before that, he acted as CEO of Biogenesis Bagó; a regional biotech company of animal health products and services. President at Caprove (Camara Argentina de la Industria de Productos Veterinarios). He holds a degree in Medical Veterinary.

DAY 3, 27th Sept 2017		
Day 3, 27th Sept 2017	**9:00 – 10:40**	**Regulatory Forum**
Chair: **Dr. Yeowon Sohn** 	Former Director General, MFDS, Korea	Dr. Sohn served as the Director-General of Biopharmaceuticals and Herbal Medicines Evaluation Department at MFDS, Korea. She has more than 25 years of experience in regulating biological products including vaccines, blood products, recombinant therapeutic proteins, gene and cell therapy products. She holds Ph.D. in Pharmacy (Biochemistry) from Seoul National University and a postdoctorate from the University of Wisconsin.
Co-Chair: **Dr. Nora Dellepiane** 	Independent Consultant	With 40 years of experience in production and control of Biological Products, she spent the past twenty years at WHO, she has experience in quality assurance, quality systems and understanding of GMP. She now focuses on assisting manufacturers of Biological Products and regulators to address challenges in the regulation of novel biologicals, and provides training.
Ms. Emer Cooke 	Head of Regulation of Medicines and Other Health Technologies, WHO	Emer Cooke was appointed Head of Regulation of Medicines and other Health Technologies. She is from Ireland and was Head of International Affairs at the European Medicines Agency in London. She had worked at the Agency since 2002, during which time she also served as Head of International and European Cooperation and Head of Inspections.
Dr. Shyam Bhaskaran 	Program Officer, Regulatory affairs, Integrated Development Team, Global Health, BMGF	Dr. Bhaskaran primarily supports the Foundation's regulatory systems investments. He also manages the Global Health Regulatory Team (GHRT), facilitating collaboration and information sharing across regulatory staff at the Foundation's product development partners. He holds a PhD in Microbiology & Structural Biology from the Rockefeller University, and a MBA from Cornell University.

Dr. Nora Dellepiane 	Independent Consultant	With 40 years of experience in production and control of Biological Products, she spent the past twenty years at WHO, she has experience in quality assurance, quality systems and understanding of GMP. She now focuses on assisting manufacturers of Biological Products and regulators to address challenges in the regulation of novel biologicals, and provides training.
Dr. Bartholomew Dicky Akanmori 	Regional Advisor, Regulation of Vaccines and Biologicals, Coordinator, AVAREF secretariat	Professor Akanmori is the Regional adviser for vaccine regulation WHO Regional Office for Africa, Congo. He is responsible for research and development, building ethics and regulatory capacity for vaccine clinical trials and advising on new vaccine candidates against major infectious diseases in the African region. He coordinates the secretariat of the African Vaccine Regulatory Forum (AVAREF).
Day 3, 27th Sept 2017	**9:00 – 10:40**	**Procurement and Financing Forum**
Chair: **Dr. Rajesh Jain** 	Joint Managing Director, Panacea Biotech	Dr. Rajesh Jain serves as Joint Managing Director of Panacea Biotec Dr. Jain has an experience of around 21 years in the pharmaceutical industry in the areas of Marketing, R&D and Business Development. In view of his vast contribution in Biotechnology sector, Dr. Jain has been nominated to several positions in various forums and advisory committees.
Co-Chair: **Dr. Morena Makohana** 	CEO, Biovac	Morena is the CEO of Biovac, aiming to build vaccine manufacturing capacity in Southern Africa. Morena is a medical graduate from the University of Cape Town, South Africa. Prior to his CEO role he was Deputy CEO and Medical Affairs Director for Biovac and Litha Healthcare Group. He serves several of committees within the vaccine industry.

Ms. Tania Cernuschi 	Team Leader, Vaccine Supply, Technologies & Financing, WHO	Tania leads WHO IVB work on access to vaccine supply. She has fifteen year experience in design and management of development programmes enhancing access to health technologies in resource-constrained settings with Gavi, UNDESA, the Italian Government, UNICEF and NGOs. Tania is a development economist and public health specialist by training.
Ms. Suvi Rautio 	Deputy Director, Supply Programme in UNICEF Supply Division	Suvi Rautio is Deputy Director, Supply Programme in UNICEF Supply Division, responsible for vaccines and other health supplies. She has held several positions in UNICEF Supply Division in several countries. Before joining UNICEF, she worked in the private sector in Taiwan and Hong Kong and with the International Labour Organization in Fiji.
Ms. Melissa Malhame 	Head of Market Shaping, Gavi	Melissa is the Head of Market Shaping at Gavi, responsible for working with Alliance partners and industry to meet demand and minimizing the costs of vaccines to Gavi and countries. Melissa has 20 years' experience in vaccine development, business, marketing and sales. She received her MBA degree from Cornell University.
Dr. Els Torreele 	Executive Director, of Global Access Campaign, MSF	Dr. Torreele has a degree in bio engineering, and earned a PhD in applied biological sciences. She joined MSF in 1999. In 2009, Dr. Torreele became the director of the Access to Medicines and Innovation program at Open Society Foundations, and now she is the Executive Director Of Global MSF Access Campaign.

Day 3, 27th Sept 2017	11:00 – 12:30	Regulatory Convergence Panel Discussion
Moderator: Dr. Nora Dellepiane 	Independent Consultant	With 40 years of experience in production and control of Biological Products, she spent the past twenty years at WHO, she has experience in quality assurance, quality systems and understanding of GMP. She now focuses on assisting manufacturers of Biological Products and regulators to address challenges in the regulation of novel biologicals, and provides training.
Dr. Yeowon Sohn 	Former Director General, MFDS, Korea	Dr. Sohn served as the Director-General of Biopharmaceuticals and Herbal Medicines Evaluation Department at MFDS, Korea. She has more than 25 years of experience in regulating biological products including vaccines, blood products, recombinant therapeutic proteins, gene and cell therapy products. She holds Ph.D. in Pharmacy (Biochemistry) from Seoul National University and a postdoctorate from the University of Wisconsin.
Dr. Bartholomew Dicky Akanmori 	Regional Advisor, Regulation of Vaccines and Biologicals, Coordinator, AVAREF secretariat	Professor Bartholomew Akanmori is the Regional adviser for vaccine regulation WHO Regional Office for Africa, Congo. Since 2008, he has been responsible for research and development, building ethics and regulatory capacity for vaccine clinical trials and advising on new vaccine candidates against major infectious diseases in the African region. He coordinates the secretariat of the African Vaccine Regulatory Forum (AVAREF).
Dr. Harish Iyer 	Senior Advisor, BMGF	Harish is Senior Advisor at BMGF managing its scientific programs on issues related to Developing Countries Manufacturers and R&D; he has extensive experience in the biotechnology industry. He was previously CEO of Shanta Biotech and had previously other managing positions in Biocon. He holds a Ph.D. in Chemical Engineering from the Rensselaer Polytechnic Institute, NY.

Ms. Emer Cooke 	Head of Regulation of Medicines and Other Health Technologies, WHO	Emer Cooke was appointed Head of Regulation of Medicines and other Health Technologies. She is from Ireland and was Head of International Affairs at the European Medicines Agency in London. She had worked at the Agency since 2002, during which time she also served as Head of International and European Cooperation and Head of Inspections.
Dr. Shyam Bhaskaran 	Program Officer, Regulatory affairs, Integrated Development Team, Global Health, BMGF	Dr. Bhaskaran primarily supports the Foundation's regulatory systems investments. He also manages the Global Health Regulatory Team (GHRT), facilitating collaboration and information sharing across regulatory staff at the Foundation's product development partners. He holds a PhD in Microbiology & Structural Biology from the Rockefeller University, and a MBA from Cornell University.
Dr. Richard Hatchett 	CEO, CEPI (Coalition for Epidemic Preparedness Innovations)	Dr. Hatchett has led medical countermeasure development programs at BARDA and the U.S. NIH. He has played leading roles at HHS and the White House in designing these programs as well as in planning for and responding to H5N1 avian influenza, the 2009 H1N1 influenza pandemic, Ebola, MERS, and Zika epidemics.
Dr. Dat Tuan Do 	General Director, Vabiotech	Do Tuan Dat is General Director of VABIOTECH. He manages all the business, R&D activities and expansion of vaccine supply in Vietnamese market and global markets. Before that, he studied Tropical and Infectious Diseases in Vietnam. He holds a Ph.D in Virology from National Institute of Hygiene and Epidemiology, Vietnam.

Day 3, 27th Sept 2017	11:00 – 12:30	Innovative Procurement and Financing Panel Discussion
Moderator: Mr. Sourabh Sobti 	Senior Manager, CHAI	Sourabh Sobti is Senior Manager in Global Markets team at CHAI, supporting global vaccines and pharmaceutical manufacturers to ensure sustainable access of life-saving health commodities for low and middle income countries. Prior to CHAI, Sourabh worked as a Life Sciences management consultant at Accenture. Sourabh holds a Master of Science in Biochemical Engineering from University College London.
Ms. Suvi Rautio 	Deputy Director – Supply Programme, Supply Division, UNICEF	Suvi Rautio is UNICEF Supply Division's Deputy Director, and manages initiatives and activities to ensure life-saving products are available and affordable for UNICEF programmes and for Procurement Services partners for whom UNICEF procures.
Ms. Li Meng 	Director, CNBG	Ms. Li Meng is the Director of International Cooperation at CNBG. She is currently responsible for managing and executing major international cooperation projects. Her experience in vaccine prequalification, commercialization and cooperative research activities have given her insights in the global vaccine industry. She is also an experienced manager in fund raising, strategy and business development.
Mr. Oscar Vargas 	Procurement Specialist, PAHO	Mr. Oscar Vargas is Procurement Specialist for the Revolving Fund at PAHO/WHO (Pan American Health Organization / World Health Organization) in Washington D.C., responsible for Biological Products (Vaccines and Immunoglobulins) acquisitions. Mr. Vargas has over 20 years of experience in logistics and procurement in the private and public sectors; he is Pharmacist and holds a CIPS certification in public procurement.

Dr. Sylvie Briand 	Director, WHO Health Emergencies Programme	Dr. Briand is Director of the Infectious Hazard Management department (IHM) in the new Health Emergencies programme at WHO headquarters in Geneva, Switzerland. IHM develops global strategies to prevent and control epidemic-prone diseases under the International Health Regulations. Prior to joining WHO, she worked for a private consulting agency developing international public health projects.
Dr. Andrin Oswald 	Director, Life Sciences Partnerships, BMGF	Dr. Oswald, is the director of Life Sciences Partnerships at the foundation, overseeing the foundation's engagements with corporations. Before joining the foundation in 2016, he was the CEO and Division Head of Novartis Vaccines and Diagnostics from 2008 to 2015. He obtained his medical degree from University of Geneva.
Ms. Melissa Malhame 	Head Market Shaping, Gavi	Ms. Melissa is the Head of Market Shaping at Gavi, responsible for working with Alliance partners and industry to meet demand and minimizing the costs of vaccines to Gavi and countries. Melissa has 20 years' experience in vaccine development, business, marketing and sales. She received her MBA degree from Cornell University.

Day 3, 27th Sept 2017	**14:00 – 15:00**	**Technology Transfer Forum**
Chair: **Dr. Viliam Pavliak** 	Head of Vaccine Development Science Unit, International Vaccine Institute	Dr. Pavliak obtained his PhD in Biochemistry from the Slovak Technical University. Prior joining IVI, he was Director at Pfizer Vaccine Research and Development, and at Wyeth Research in USA. He previously led preclinical development and evaluation of several vaccines at Nabi and Univax Biologics. He is also member of the Scientific Advisory Board of GlycoNet.

Co-Chair: **Mr. Samir Desai** 	Sr. Vice President & SBU Head Zydus Cadila Healthcare Ltd.	Industry experience of close to 3 decades having handled sales, training, brand management, marketing and commercial operations. Current role includes commercial operations for vaccines & biologics and small molecules across specialties & geographies, Business Development, In & Out licensing, portfolio planning. Extensively worked in the area of maternal health related public policy advocacy.
Dr. Moon H. Nahm 	University of Alabama at Birmingham	Professor Moon H. Nahm is at the University of Alabama at Birmingham in USA. He received his MD, medical training and post-doctoral research training at Washington University in St. Louis, USA. He has studied pneumococcal infections and vaccines for more than 30 years. His laboratory serves as Reference Laboratories for the US NIH and WHO.
Mr. Atin Tomar 	President & CEO, Cadila Pharmaceuticals Limited (CPL)	Atin Tomar is President & CEO of CPL Biologicals. Atin brings with him comprehensive experience in Biotechnology industry in the areas of Vaccines and Biologics, globally. Atin's expertise spans from Process Development, Scale-up, Technology Transfer and Manufacturing Operations to Business Development, Licensing and Commercialization.
Mr. Abdul Muktadir 	Chairman, Managing Director, Incepta Pharmaceuticals & Vaccines	Abdul Muktadir is the Chairman and Managing Director of Incepta Vaccine and Incepta Pharmaceuticals. He has a degree in Industrial Pharmacy from USA. Abdul Muktadir has dedicated himself in developing vaccine facility in Bangladesh for the first time with a hope to manufacture vaccines from own bulk at affordable cost.

Day 3, 27th Sept 2017	14:00 – 15:00	WHO PQ Session
Chair: **Ms. Emer Cooke** 	Head of Regulation of Medicines and Other Health Technologies, WHO	Emer Cooke was appointed Head of Regulation of Medicines and other Health Technologies. She is from Ireland and was Head of International Affairs at the European Medicines Agency in London. She had worked at the Agency since 2002, during which time she also served as Head of International and European Cooperation and Head of Inspections.
Co-Chair: **Dr. Nora Dellepiane** 	Independent Consultant	With 40 years of experience in production and control of Biological Products, she spent the past twenty years at WHO, she has experience in quality assurance, quality systems and understanding of GMP. She now focuses on assisting manufacturers of Biological Products and regulators to address challenges in the regulation of novel biologicals, and provides training.
Ms. Carmen Rodriguez 	Group Lead, Vaccines PQ HIS/EMP/RHT/PQ WHO	Ms. Rodriguez is the Group leader of Vaccines PQ. She is a pharmacist with specialization in Microbiology. Ms. Rodriguez has twenty-six years of experience in the area of regulation of biologicals, and several publications in the area of quality control of vaccines. She is responsible for the Assessment of vaccines for prequalification.
Dr. Andrew Meek 	Scientist, HIS/EMP/RHT/PQT, WHO	1987 : PhD in Molecular Virology (ANU) 1989-2005: Therapeutic Goods Administration [regulation of vaccines and other biologics] included WHO collaborative centre activities. 2005-2006 (WHO Iran): project manager - strengthening NRA's vaccine regulation. 2007- to date: WHO, Prequalification Team (PQT) with focus on quality and programmatic suitability aspects of vaccines.

Day 3, 27th Sept 2017	15:00 – 16:00	Innovative Vaccines Session
Chair: Dr. Hun Kim 	Vice President, Head of Bio R&BD, SK Chemicals	Dr. Hun Kim is head of Vaccine Research & Business Development at SK Chemicals. Dr. Kim's role at the company is to oversee its vaccine portfolios from both the business and R&D perspective. Under his oversight as Head of R&D, the company successfully developed and received approval for cell-culture based influenza vaccine products, SKYCellflu.
Co-Chair: Mr. Sai Prasad 	President, Bharat Biotech International	Sai is President at Bharat Biotech, responsible for product development and commercialization of vaccines and biologics. In his previous role as Vice President for Business Development and Strategy, he handled operational and strategic activities. Before that he was the Director of Molecular Otolaryngology Research Laboratories at the University of Iowa. He holds a biochemistry degree from Wisconsin University and a M.B.A from the Iowa University.
Mr. Patrick Tippoo 	Head of Science & Innovation, The Biovac Institute	Patrick Tippoo heads the Product Development and Business Development at The Biovac Institute. He has been with Biovac since its inception in 2003. Patrick's responsibilities include strategic alliances and local & international partnering opportunities with respect to product development and inbound and outbound technology transfer projects.
Dr. Suresh Jadhav 	Executive Director, Serum Institute of India	Dr. Jadhav is the Executive Director of Serum Institute of India, and was DCVMN's President from 2003 to 2008. He was member on GAVI Board & PPC. He is currently member on European Vaccine Initiative, FastVac and HIP. He is active in several collaborative studies and has published more than 95 technical papers in national & international journals.

Dr. Yeong-Ok Baek 	CEO, EuBiologics	Dr Yeong-ok Baek has more than 30 years of experience in biotechnology industry starting his career at CJ Corporation. He founded EuBiologics Co., Ltd in 2010 and is currently the CEO. He graduated from Seoul National University in Veterinary Medicine and has a Ph.D. in Life Science from Korea University.
Dr. Min-Shi Lee 	Investigator and Project Leader, National Institute of Infectious Diseases and Vaccinology (NIIDV),Taiwan	Dr. Min-Shi Lee is an investigator working on development of enterovirus and pandemic influenza vaccines in National Institute of Infectious Diseases and Vaccinology, NHRI, Taiwan. Before joining NHRI, Dr. Lee worked on development of intranasal influenza and parainfluenza vaccines in MedImmune Vaccines. Dr. Lee holds a PhD degree from University of Oxford.

Day 3, 27th Sept 2017	15:00 – 16:00	Polio Vaccines Session
Chair: **Dr. Akira Homma** 	Senior Advisor, Bio-Manguinhos/ Fiocruz	Dr. Homma serves as Senior Scientific and Technological Advisor to Bio-Manguinhos. He graduated in Veterinary Medicine, and received a D.Sci at School of Medicine of São Paulo University and post-graduate in Virology from Baylor College of Medicine in Houston. He published more than 60 papers in the biological area and occupied several executive and advisory positions.
Co-Chair: **Ms. Anna-Lea Kahn** 	Technical Officer, EPI/IVB, WHO	Ms. Anna-Lea Kahn works in the Expanded Program on Immunization at the World Health Organization, focusing on logistics and innovation since 2014. Previously, she spent ten years in the research and policy team of the Polio Eradication Initiative. She earned her MSc from the London School of Hygiene and Tropical Medicine.
Ms. Simona Zipursky 	WHO Advisor	Simona Zipursky is the Advisor to the Director, Polio Eradication at WHO, where she coordinates the Global Polio Eradication Initiative (GPEI's) Strategy Committee. Prior to joining Polio, Simona worked for the immunization department at WHO, where she coordinated the work to introduce IPV and the globally synchronized withdrawal of bOPV.
Mr. Ian Lewis 	Contract Specialist, Vaccine Centre, UNICEF Supply Division	Mr. Lewis is working at UNICEF Supply Division in the Polio Unit within the Vaccine Centre. Main responsibilities are the supply management of IPV and OPV vaccines.

Mr. Yuntao Zhang 	Associate President, TiantanBio	Dr.Zhang is the Associate President of CNBG, overseeing R&D and international cooperation. He previously was deputy GM of National Vaccine and Serum Institute. He spent over 20 years in research field, successfully led the clinical development of EV71, played major roles in developing a series of vaccines, diagnostic reagents and antibodies.
Ms. Li Meng 	Director International Cooperation, CNBG	Li Meng is the Director of International Cooperation at CNBG. She is currently responsible for managing and executing major international cooperation projects. Her experience in vaccine prequalification, commercialization and cooperative research activities have given her insights in the global vaccine industry. She is also an experienced manager in fund raising, strategy and business development.
Dr. Mas Rahman Roestan 	Marketing Director, Bio Farma	Dr. Roestan, Marketing Director of Bio Farma Indonesia, occupied various positions including Corporate Secretary, Team leader of Integrated Management System for ISO 9001, ISO 14001 & OHSAS 18001, Senior Manager of Production Plan and Inventory Control. Major successes include the development and establishment of Innovation System and Enterprise Risk Management in the Company.

Day 3, 27th Sept 2017	16:30-17:30	Plenary Closing Session
Chair: **Ms. Mahima Datla** 	Managing Director, Biological E	Mahima Datla oversees strategic operations within Biological E organization and related to public policy. She has been with BE for 19 years and has served across a diverse range of functions. Mahima is also the President of DCVMN's Executive Committee, and is currently a member of CII National Biotech committees and a GHIT fund board member.
Co-Chair: **Dr. Vicente V. Bencomo** 	Dr V. Verez Bencomo General Director Finlay Vaccine Institute	Professor Verez was the Leader of the group developing the first Haemophilus influenza type-b vaccine made from a fully synthetic antigen for human use, named QuimiHib, introduced in several countries and presently prequalified by the WHO. He is a chemical engineer and holds a master in technology of Moscow Institute of Fine Chemical Technology, and a Docteur d'Etat, Université d Orleans, France.
Dr. Martin Friede 	Coordinator, IVR, WHO	Martin Friede is the coordinator of the Initiative for Vaccine research (IVR) at the World Health Organization in Geneva, Switzerland. In this position Dr. Friede provides leadership to WHO's activities on vaccine research including development of vaccine research policies, strategies and priorities. He also leads the WHO Blueprint for R&D to prevent epidemics.